Browsing Molecular Pathology by title
Now showing items 52-71 of 888
-
Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence.
(NATURE PORTFOLIO, 2021-09-17)The specific niche adaptations that facilitate primary disease and Acute Lymphoblastic Leukaemia (ALL) survival after induction chemotherapy remain unclear. Here, we show that Bone Marrow (BM) adipocytes dynamically evolve ... -
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
(ELSEVIER, 2020-11-08)BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ... -
Advances in immunotherapy for MMR proficient colorectal cancer.
(ELSEVIER SCI LTD, 2022-12-01)Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect ... -
Advances in mass spectrometry based strategies to study receptor tyrosine kinases.
(INT UNION CRYSTALLOGRAPHY, 2017-02-23)Receptor tyrosine kinases (RTKs) are key transmembrane environmental sensors that are capable of transmitting extracellular information into phenotypic responses, including cell proliferation, survival and metabolism. ... -
Advances in the proteomic profiling of the matrisome and adhesome.
(TAYLOR & FRANCIS LTD, 2021-09-02)INTRODUCTION: The matrisome and adhesome comprise proteins that are found within or are associated with the extracellular matrix (ECM) and adhesion complexes, respectively. Interactions between cells and their microenvironment ... -
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
(SPRINGER, 2020-08-01)The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in ... -
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma.
(NATURE PUBLISHING GROUP, 2019-05-09)Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2. Despite being an amenable drug ... -
Amino acid dependence in acute myeloid leukaemia
(Institute of Cancer Research (University Of London), 2022-05-31)Acute myeloid leukaemia (AML) is a heterogeneous disease which remains curable in only a minority of patients. Outcome is dismal in the subgroup with adverse genetic features. Amino acid (AA) depletion is a therapeutic ... -
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.
(TAYLOR & FRANCIS LTD, 2022-01-02)INTRODUCTION: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations ... -
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.
(BMC, 2015-09-22)INTRODUCTION: Abundance of immune cells has been shown to have prognostic and predictive significance in many tumor types. Beyond abundance, the spatial organization of immune cells in relation to cancer cells may also ... -
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.
(SPRINGERNATURE, 2020-10-14)Most patients with multiple myeloma (MM) die from progressive disease after relapse. To advance our understanding of MM evolution mechanisms, we performed whole-genome sequencing of 80 IGH-translocated tumour-normal newly ... -
An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2017-09-01)Chemotherapy remains the mainstay of treatment for advanced breast cancer; however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available ... -
Anal squamous cell carcinoma in a high HIV prevalence population.
(SPRINGER, 2021-02-11)Anal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of ... -
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
(AMER ASSOC CANCER RESEARCH, 2017-09-01)Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) ... -
Analysis of novel therapeutic options for adenoid cystic carcinoma of the salivary glands
(Institute of Cancer Research (University Of London), 2021-04-30)Adenoid cystic adenocarcinoma (ACC) of the salivary glands is characterised by slow growth, frequent metastasis and low survival rates. ACC is resistant to conventional chemotherapy and currently, no systemic agent has ... -
Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer.
(ELSEVIER, 2019-10-21)BACKGROUND: Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ... -
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
(2019-08)Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ... -
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
(NATURE PORTFOLIO, 2019-05-21)Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ... -
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
(NATURE PUBLISHING GROUP, 2015-03-31)BACKGROUND: Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based ...